Lung disease in rheumatoid arthritis

Rheumatic Disease Clinics of North America

Volumn 41, Issue 2, 2015, Pages 225-236

  Yunt, Zulma X ^a   Solomon, Joshua J ^a  

^a DEPARTMENT OF MEDICINE   (United States)

Author keywords

Bronchiolitis; Drug induced lung disease; Extra articular disease; Interstitial lung disease; Interstitial pneumonia; Pleural effusion; Pulmonary; Rheumatoid arthritis

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR ANTIBODY;

AMYLOIDOSIS; BRONCHIECTASIS; BRONCHIOLITIS OBLITERANS; CRICOARYTENOID ARTHRITIS; EMPYEMA; FOLLICULAR BRONCHIOLITIS; HUMAN; INCIDENCE; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LUNG DISEASE; LUNG INFECTION; LUNG TOXICITY; LYMPHOCYTIC INTERSTITIAL PNEUMONIA; MORTALITY; ORGANIZING PNEUMONIA; PLEURA EFFUSION; PLEURISY; PNEUMOCONIOSIS; PNEUMOTHORAX; PREVALENCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; RHEUMATOID ARTHRITIS; RHEUMATOID NODULE; RHEUMATOID VASCULITIS; USUAL INTERSTITIAL PNEUMONIA; COMPLICATION; LUNG DISEASES; PATHOPHYSIOLOGY;

ARTHRITIS, RHEUMATOID; HUMANS; LUNG DISEASES;

EID: 84926170727     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2014.12.004     Document Type: Review

References (81)

1. Lee H.K., Kim D.S., Yoo B., et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest 2005, 127(6):2019-2027. [Key Reference].
2. Gabriel S.E., Crowson C.S., Kremers H.M., et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 2003, 48(1):54-58.
3. Turesson C., O'Fallon W.M., Crowson C.S., et al. Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. JRheumatol 2002, 29(1):62-67.
4. Bilgici A., Ulusoy H., Kuru O., et al. Pulmonary involvement in rheumatoid arthritis. Rheumatol Int 2005, 25(6):429-435.
5. Mori S., Cho I., Koga Y., et al. Comparison of pulmonary abnormalities on high-resolution computed tomography in patients with early versus longstanding rheumatoid arthritis. JRheumatol 2008, 35(8):1513-1521.
6. Dawson J.K., Fewins H.E., Desmond J., et al. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. Thorax 2001, 56(8):622-627.
7. Young A., Koduri G., Batley M., et al. Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology (Oxford) 2007, 46(2):350-357.
8. Thomas E., Symmons D.P., Brewster D.H., et al. National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year followup study. JRheumatol 2003, 30(5):958-965.
9. Suzuki A., Ohosone Y., Obana M., et al. Cause of death in 81 autopsied patients with rheumatoid arthritis. JRheumatol 1994, 21(1):33-36.
10. Sihvonen S., Korpela M., Laippala P., et al. Death rates and causes of death in patients with rheumatoid arthritis: a population-based study. Scand J Rheumatol 2004, 33(4):221-227.
11. Turesson C., Jacobsson L., Bergstrom U. Extra-articular rheumatoid arthritis: prevalence and mortality. Rheumatology (Oxford) 1999, 38(7):668-674.
12. Travis W.D., Costabel U., Hansell D.M., et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013, 188(6):733-748.
13. Nakamura Y., Suda T., Kaida Y., et al. Rheumatoid lung disease: prognostic analysis of 54 biopsy-proven cases. Respir Med 2012, 106(8):1164-1169.
14. Kim E.J., Elicker B.M., Maldonado F., et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 2010, 35(6):1322-1328. [Key Reference].
15. Solomon J.J., Brown K.K. Rheumatoid arthritis-associated interstitial lung disease. Open Access Rheumatol Res Rev 2012, (4):21-31.
16. Charles P.J., Sweatman M.C., Markwick J.R., et al. HLA-B40: a marker for susceptibility to lung disease in rheumatoid arthritis. Dis Markers 1991, 9(2):97-101. [Key Reference].
17. Scott T.E., Wise R.A., Hochberg M.C., et al. HLA-DR4 and pulmonary dysfunction in rheumatoid arthritis. Am J Med 1987, 82(4):765-771. [Key Reference].
18. Hillarby M.C., McMahon M.J., Grennan D.M., et al. HLA associations in subjects with rheumatoid arthritis and bronchiectasis but not with other pulmonary complications of rheumatoid disease. Br J Rheumatol 1993, 32(9):794-797. [Key Reference].
19. Sugiyama Y., Ohno S., Kano S., et al. Diffuse panbronchiolitis and rheumatoid arthritis: a possible correlation with HLA-B54. Intern Med 1994, 33(10):612-614. [Key Reference].
20. Gochuico B.R., Avila N.A., Chow C.K., et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med 2008, 168(2):159-166. [Key Reference].
21. Albano S.A., Santana-Sahagun E., Weisman M.H. Cigarette smoking and rheumatoid arthritis. Semin Arthritis Rheum 2001, 31(3):146-159.
22. Demoruelle M.K., Deane K.D., Holers V.M. When and where does inflammation begin in rheumatoid arthritis?. Curr Opin Rheumatol 2014, 26(1):64-71.
23. Makrygiannakis D., Hermansson M., Ulfgren A.K., et al. Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. Ann Rheum Dis 2008, 67(10):1488-1492. [Key Reference].
24. Willis V.C., Demoruelle M.K., Derber L.A., et al. Sputum autoantibodies in patients with established rheumatoid arthritis and subjects at risk of future clinically apparent disease. Arthritis Rheum 2013, 65(10):2545-2554.
25. Harlow L., Rosas I.O., Gochuico B.R., et al. Identification of citrullinated hsp90 isoforms as novel autoantigens in rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheum 2013, 65(4):869-879.
26. Giles J.T., Danoff S.K., Sokolove J., et al. Association of fine specificity and repertoire expansion of anticitrullinated peptide antibodies with rheumatoid arthritis associated interstitial lung disease. Ann Rheum Dis 2014, 73(8):1487-1494.
27. Chen J., Doyle T.J., Liu Y., et al. Biomarkers of rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheum 2015, 67(1):28-38.
28. Olson A.L., Swigris J.J., Sprunger D.B., et al. Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med 2011, 183(3):372-378.
29. Bongartz T., Nannini C., Medina-Velasquez Y.F., et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum 2010, 62(6):1583-1591.
30. Solomon J.J., Ryu J.H., Tazelaar H.D., et al. Fibrosing interstitial pneumonia predicts survival in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). Respir Med 2013, 107(8):1247-1252.
31. Assayag D., Lubin M., Lee J.S., et al. Predictors of mortality in rheumatoid arthritis-related interstitial lung disease. Respirology 2014, 19(4):493-500.
32. Park J.H., Kim D.S., Park I.N., et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 2007, 175(7):705-711.
33. Perez T., Remy-Jardin M., Cortet B. Airways involvement in rheumatoid arthritis: clinical, functional, and HRCT findings. Am J Respir Crit Care Med 1998, 157(5 Pt 1):1658-1665. [Key Reference].
34. Fischer A., Brown K.K., Du Bois R.M., et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. JRheumatol 2013, 40(5):640-646.
35. Swigris J.J., Olson A.L., Fischer A., et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 2006, 130(1):30-36.
36. Keir G.J., Maher T.M., Ming D., et al. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology 2014, 19(3):353-359.
37. Braun-Moscovici Y., Butbul-Aviel Y., Guralnik L., et al. Rituximab: rescue therapy in life-threatening complications or refractory autoimmune diseases: a single center experience. Rheumatol Int 2013, 33(6):1495-1504.
38. Chang H.K., Park W., Ryu D.S. Successful treatment of progressive rheumatoid interstitial lung disease with cyclosporine: a case report. JKorean Med Sci 2002, 17(2):270-273. [Key Reference].
39. Puttick M.P., Klinkhoff A.V., Chalmers A., et al. Treatment of progressive rheumatoid interstitial lung disease with cyclosporine. JRheumatol 1995, 22(11):2163-2165.
40. Bargagli E., Galeazzi M., Rottoli P. Infliximab treatment in a patient with rheumatoid arthritis and pulmonary fibrosis. Eur Respir J 2004, 24(4):708.
41. Vassallo R., Matteson E., Thomas C.F. Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-alpha inhibition. Chest 2002, 122(3):1093-1096.
42. Lindsay K., Melsom R., Jacob B.K., et al. Acute progression of interstitial lung disease: a complication of etanercept particularly in the presence of rheumatoid lung and methotrexate treatment. Rheumatology (Oxford) 2006, 45(8):1048-1049.
43. Ostor A.J., Crisp A.J., Somerville M.F., et al. Fatal exacerbation of rheumatoid arthritis associated fibrosing alveolitis in patients given infliximab. BMJ 2004, 329(7477):1266.
44. Dixon W.G., Hyrich K.L., Watson K.D., et al. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2010, 69(6):1086-1091.
45. Yazdani A., Singer L.G., Strand V., et al. Survival and quality of life in rheumatoid arthritis-associated interstitial lung disease after lung transplantation. JHeart Lung Transplant 2014, 33(5):514-520.
46. Geddes D.M., Webley M., Emerson P.A. Airways obstruction in rheumatoid arthritis. Ann Rheum Dis 1979, 38(3):222-225.
47. Collins R.L., Turner R.A., Johnson A.M., et al. Obstructive pulmonary disease in rheumatoid arthritis. Arthritis Rheum 1976, 19(3):623-628.
48. Hassan W.U., Keaney N.P., Holland C.D., et al. Bronchial reactivity and airflow obstruction in rheumatoid arthritis. Ann Rheum Dis 1994, 53(8):511-514.
49. Brazeau-Lamontagne L., Charlin B., Levesque R.Y., et al. Cricoarytenoiditis: CT assessment in rheumatoid arthritis. Radiology 1986, 158(2):463-466.
50. Metafratzi Z.M., Georgiadis A.N., Ioannidou C.V., et al. Pulmonary involvement in patients with early rheumatoid arthritis. Scand J Rheumatol 2007, 36(5):338-344.
51. Kochbati S., Boussema F., Ben Miled M., et al. Bronchiectasis in rheumatoid arthritis. High resolution computed pulmonary tomography. Tunis Med 2003, 81(10):768-773. [in French].
52. Geri G., Dadoun S., Bui T., et al. Risk of infections in bronchiectasis during disease-modifying treatment and biologics for rheumatic diseases. BMC Infect Dis 2011, 11:304.
53. Pipavath S.J., Lynch D.A., Cool C., et al. Radiologic and pathologic features of bronchiolitis. AJR Am J Roentgenol 2005, 185(2):354-363.
54. Fernandez Perez E.R., Krishnamoorthy M., Brown K.K., et al. FEV1 over time in patients with connective tissue disease-related bronchiolitis. Respir Med 2013, 107(6):883-889.
55. Devouassoux G., Cottin V., Liote H., et al. Characterisation of severe obliterative bronchiolitis in rheumatoid arthritis. Eur Respir J 2009, 33(5):1053-1061.
56. Anaya J.M., Diethelm L., Ortiz L.A., et al. Pulmonary involvement in rheumatoid arthritis. Semin Arthritis Rheum 1995, 24(4):242-254.
57. Walters M.N., Ojeda V.J. Pleuropulmonary necrobiotic rheumatoid nodules. A review and clinicopathological study of six patients. Med J Aust 1986, 144(12):648-651.
58. Morikawa J., Kitamura K., Habuchi Y., et al. Pulmonary hypertension in a patient with rheumatoid arthritis. Chest 1988, 93(4):876-878.
59. Voskuyl A.E., Hazes J.M., Zwinderman A.H., et al. Diagnostic strategy for the assessment of rheumatoid vasculitis. Ann Rheum Dis 2003, 62(5):407-413.
60. Avnon L.S., Abu-Shakra M., Flusser D., et al. Pleural effusion associated with rheumatoid arthritis: what cell predominance to anticipate?. Rheumatol Int 2007, 27(10):919-925.
61. Naylor B. The pathognomonic cytologic picture of rheumatoid pleuritis. The 1989 Maurice Goldblatt Cytology award lecture. Acta Cytol 1990, 34(4):465-473.
62. Kremer J.M., Alarcon G.S., Weinblatt M.E., et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum 1997, 40(10):1829-1837.
63. Walden P.A., Mitchell-Weggs P.F., Coppin C., et al. Pleurisy and methotrexate treatment. Br Med J 1977, 2(6091):867.
64. Cannon G.W., Ward J.R., Clegg D.O., et al. Acute lung disease associated with low-dose pulse methotrexate therapy in patients with rheumatoid arthritis. Arthritis Rheum 1983, 26(10):1269-1274.
65. St Clair E.W., Rice J.R., Snyderman R. Pneumonitis complicating low-dose methotrexate therapy in rheumatoid arthritis. Arch Intern Med 1985, 145(11):2035-2038.
66. Gispen J.G., Alarcon G.S., Johnson J.J., et al. Toxicity of methotrexate in rheumatoid arthritis. JRheumatol 1987, 14(1):74-79.
67. Amital A., Shitrit D., Adir Y. The lung in rheumatoid arthritis. Presse Med 2011, 40(1 Pt 2):e31-e48.
68. Barrera P., Laan R.F., van Riel P.L., et al. Methotrexate-related pulmonary complications in rheumatoid arthritis. Ann Rheum Dis 1994, 53(7):434-439.
69. Toussirot E., Berthelot J.M., Pertuiset E., et al. Pulmonary nodulosis and aseptic granulomatous lung disease occurring in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha-blocking agent: a case series. J Rheumatol 2009, 36(11):2421-2427.
70. Peno-Green L., Lluberas G., Kingsley T., et al. Lung injury linked to etanercept therapy. Chest 2002, 122(5):1858-1860.
71. Dubey S., Kerrigan N., Mills K., et al. Bronchospasm associated with anti-TNF treatment. Clin Rheumatol 2009, 28(8):989-992.
72. Atzeni F., Boiardi L., Salli S., et al. Lung involvement and drug-induced lung disease in patients with rheumatoid arthritis. Expert Rev Clin Immunol 2013, 9(7):649-657.
73. Roubille C., Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review. Semin Arthritis Rheum 2014, 43(5):613-626.
74. Sakai F., Noma S., Kurihara Y., et al. Leflunomide-related lung injury in patients with rheumatoid arthritis: imaging features. Mod Rheumatol 2005, 15(3):173-179.
75. Suissa S., Hudson M., Ernst P. Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Arthritis Rheum 2006, 54(5):1435-1439.
76. Liote H., Liote F., Seroussi B., et al. Rituximab-induced lung disease: a systematic literature review. Eur Respir J 2010, 35(3):681-687.
77. Parry S.D., Barbatzas C., Peel E.T., et al. Sulphasalazine and lung toxicity. Eur Respir J 2002, 19(4):756-764.
78. Hamadeh M.A., Atkinson J., Smith L.J. Sulfasalazine-induced pulmonary disease. Chest 1992, 101(4):1033-1037.
79. Ikegawa K., Hanaoka M., Ushiki A., et al. Acase of organizing pneumonia induced by tocilizumab. Intern Med 2011, 50(19):2191-2193.
80. Kawashiri S.Y., Kawakami A., Sakamoto N., et al. Afatal case of acute exacerbation of interstitial lung disease in a patient with rheumatoid arthritis during treatment with tocilizumab. Rheumatol Int 2012, 32(12):4023-4026.
81. Nishimoto N., Yoshizaki K., Miyasaka N., et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004, 50(6):1761-1769.